News Merck KGaA

Equities

Market Closed - Xetra Other stock markets 16:38:26 11/03/2026 GMT			5-day change	1st Jan Change
111.00 ^EUR	0.00%		-9.79%	-9.46%

03-09	MERCK KGAA : Goldman Sachs reiterates its Buy rating	ZD
03-09	MERCK KGAA : Deutsche Bank sticks Neutral	ZD

03-09	MERCK KGAA : Goldman Sachs reiterates its Buy rating	ZD
03-09	MERCK KGAA : Deutsche Bank sticks Neutral	ZD
03-09	MERCK KGAA : Barclays reiterates its Neutral rating	ZD
03-06	MERCK KGAA : DZ Bank keeps its Buy rating	ZD
03-06	MERCK KGAA : Deutsche Bank sticks Neutral	ZD
03-05	Health Care Down on Retreat From Biotech - Health Care Roundup	DJ
03-05	German Shares Slip; DHL Group Down on Cautious Outlook	MT
03-05	Merck: Q4 miss and slightly weak 2026 guidance
03-05	Merck KGaA, Q4 2025 Earnings Call, Mar 05, 2026
03-05	Merck to expand China investment, Xinhua reports	RE
03-05	MERCK KGAA : Barclays reaffirms its Neutral rating	ZD
03-05	MERCK KGAA : Gets a Buy rating from JP Morgan	ZD
03-05	Merck KGaA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-05	Merck Outlook Disappoints – MS Drug Patent Loss Weighs on Forecast	RE
03-05	Merck Shares Under Pressure – UBS: Forecast Is Confusing	DP
03-05	Merck KGaA, Q4 2025 Earnings Call, Mar 05, 2026
03-05	MERCK KGAA : UBS reiterates its Buy rating	ZD
03-05	UBS Maintains 'Buy' Rating on Merck KGaA — Target Price Set at €150	DP
03-05	European Midday Briefing : Shares Extend Gains as Investors Embrace Risk	DJ
03-05	Merck KGaA Proposes Dividend	CI
03-05	Merck KGaA Provides Earnings Guidance for the Year 2026	CI
03-05	MERCK KGAA : Receives a Buy rating from Goldman Sachs	ZD
03-05	Merck : ESG Presentation	PU
03-05	Patent Loss for Blockbuster Drug Pressures Merck Forecast	RE
03-05	Merck KGaA sees earnings drop on currency effects, MS drug	RE